368 results about "Therapeutic strategy" patented technology

The invention discloses application of a stem cell exosome in treating depression-like behaviors caused by high-altitude hypoxia, and belongs to the technical field of biomedicine. The stem cell exosome is an exosome derived from human umbilical cord mesenchymal stem cells, and is used for drugs for preventing and / or treating depression-like behaviors caused by high-altitude hypoxia. The exosome can effectively improve depression-like core behavior symptoms caused by high-altitude hypoxia by regulating a brain-intestinal axis; the method starts from remodeling intestinal flora so as to influence the intracerebral metabolite spectrum, and finally plays a role in neuroprotection by regulating and controlling a 5-HT6 / cAMP-PKA key signal channel. In addition, the combination of the hUC-MSC-exo and probiotics shows synergistic interaction potential, and a potential treatment strategy which is novel in mechanism, remarkable in effect and high in safety is provided for the field.

The invention relates to the technical field of biomedicine, in particular to a liver cancer molecular subtype typing and prognosis model construction method based on glycometabolism and lactic acid metabolism related genes and application thereof. According to the invention, the typing and prognosis model of liver cancer subtypes is constructed for the first time on the basis of a coordinated regulation network of a glycometabolism gene and a lactic acid metabolism gene, the constructed liver cancer subtype subtypes comprise Cluster1 and Cluster2, and the total survival rates of different subtypes have significant difference; the clinical characteristics T.stage and TNM.stage of different subtypes are obviously different from each other; 12 kinds of immune cells have significant differences among different subtypes; iPS immune scores of different subtypes are significantly different; the TIDE scores of different subtypes have significant score differences; the genes with the highest mutation frequency in different subtypes comprise TP53, CTNNB1 and TTN. CLM scores of the prognosis model constructed on the basis of the collaborative regulation network of the glycometabolism genes and the lactic acid metabolism genes have no significant difference in different patient states; the 17 immune cells have significant differences between high and low risk groups. And a new way is provided for individualized treatment strategy formulation and survival outcome improvement of HCC.

The invention discloses an extraction method of safflower leaf exosome-like nano-vesicles and application of the safflower leaf exosome-like nano-vesicles in preparation of drugs for preventing and treating adriamycin-induced cardiotoxicity, fresh safflower leaves are taken and cleaned, a PBS solution is added for crushing and filtering, filtrate is collected and continuously centrifuged, supernate is taken and subjected to ultracentrifugation, precipitates are collected after centrifugation, and the safflower leaf exosome-like nano-vesicles are obtained; and filtering and sterilizing by using a filter membrane to obtain the safflower leaf exosome-like nano-vesicles. The carthamus tinctorius leaf exosome-like nano-vesicles can significantly improve the heart function of doxorubicin-induced cardiotoxic mice; myocardial injury induced by doxorubicin can be repaired, and myocardial fibrosis induced by doxorubicin can be inhibited; the content of a myocardial injury marker lactic dehydrogenase in body serum can be reduced, a new treatment strategy is provided for preventing and treating adriamycin-induced cardiotoxic diseases, and the application prospect is good.

The invention relates to the technical field of biological medicine, in particular to an ulcerative colitis disease clearance evaluation molecular marker and application thereof. By detecting the expression level of the HMGCS2 gene in a sample, the ulcerative colitis disease clearance state and disease activity period can be evaluated, and the method is used for curative effect monitoring, recurrence prediction and individualized treatment strategy formulation of ulcerative colitis and has important clinical application value and market prospect.

The invention discloses an endogenous small molecule metabolite for treating obesity and related metabolic diseases thereof, and belongs to the field of biological medicine. Specifically, the invention relates to application of hippuric acid in preparation of anti-obesity drugs. The invention discloses a technical scheme for treating obesity and related metabolic disorders by hippuric acid, and overcomes the defects of single curative effect, larger side effect or unclear action mechanism and the like in the prior art through the advantages of targeted improvement of liver fatty degeneration, improvement of insulin sensitivity, higher potential safety, provision of a new treatment strategy and the like. The method has remarkable technical progress and clinical application value.

The invention discloses a black phosphorus hydrogel microneedle patch loaded with trained mesenchymal stem cells as well as a preparation method and application of the black phosphorus hydrogel microneedle patch, and belongs to the technical field of biological medicines. The micro-needle patch comprises a hydrogel substrate layer loaded with black phosphorus nanosheets and a hydrogel needle tip part for packaging the stem cells. The mesenchymal stem cells are subjected to combined domestication with low oxygen and high active oxygen, so that the anti-oxidative stress, anti-inflammatory and angiogenesis promoting capabilities of the mesenchymal stem cells are remarkably enhanced. After the patch is subcutaneously delivered, the black phosphorus component can efficiently remove bacteria and reduce drug resistance; after being domesticated, the stem cells can adapt to the immune microenvironment of the wound surface, and the immune regulation, inflammation inhibition and tissue regeneration promotion are synergistically realized by continuously releasing anti-inflammatory and angiogenesis promoting factors, so that the refractory wound surface caused by immune disorders such as systemic lupus erythematosus (SLE) and the like is effectively treated. The invention provides an innovative treatment strategy for chronic inflammatory wound healing.

The application discloses a use of total iridoid glycosides in radix morindae officinalis in preparation of a medicine for reducing side effects of methotrexate, and the total iridoid glycosides in radix morindae officinalis are effective traditional Chinese medicine components prepared by extraction and separation from radix morindae officinalis medicinal materials. The total iridoid glycosides in radix morindae officinalis and main component crystal larkspur glycoside are combined with methotrexate to treat rheumatoid arthritis rats, and the animal experiment proves that the combined administration can effectively treat inflammation of the rheumatoid arthritis rats, and can inhibit bone loss, especially can effectively reduce side effects caused by methotrexate, reduce damage caused by methotrexate to the organism, make the application more safe and effective, and provide a new treatment strategy for rheumatoid arthritis.

The invention provides a model for predicting lung adenocarcinoma prognosis and immunotherapy response based on copper death related LncRNAs, and belongs to the technical field of bioinformatics. According to the prediction model provided by the invention, the accuracy and the stability of prognosis judgment of a lung adenocarcinoma patient can be remarkably improved, and the defects of a traditional staging system in the aspects of reflecting tumor heterogeneity and individual treatment reaction difference are effectively overcome; the model not only can realize reliable individual risk grading, but also can further evaluate the tumor immune microenvironment state and predict the potential reaction of a patient to immunotherapy, so that a powerful auxiliary tool is provided for clinically formulating an accurate treatment strategy, in particular to the application decision of an immune checkpoint inhibitor; and finally, the method has important practical application value for improving treatment selection and life quality of patients.

This invention belongs to the field of biomedical technology, specifically relating to the discovery and application of biomarkers for predicting the efficacy of immunotherapy in nasopharyngeal carcinoma. This invention provides a reliable combination of 10-gene TLS biomarkers that can effectively predict the pathological TLS status in nasopharyngeal carcinoma tissue. This 10-gene TLS biomarker combination exhibits stable and significant prognostic predictive value: regardless of standard treatment or immunotherapy, a high TLS score can effectively identify patients with better survival outcomes (such as FFS, OS, and DMFS), providing important evidence for individualized risk assessment and treatment strategy selection.

The invention belongs to the field of biological medicine, and discloses a chicoric acid (CA)-loaded tetrahedral framework nucleic acid (tFNA) nano preparation for treating acute gouty arthritis. According to the preparation, tFNA formed by self-assembly is taken as a carrier, and a natural active ingredient CA is loaded to form a CA-tFNA compound. The compound overcomes the defects that CA is poor in water solubility and low in bioavailability, and existing drugs are weak in targeting and large in side effect. Through the targeted delivery and synergistic effect of tFNA, the preparation can be effectively enriched in inflammatory joints, significantly inhibit NF-kappa B signal pathways, and down-regulate the expression of key proinflammatory factors such as TNF-alpha and IL-1beta, so that joint swelling and synovial tissue damage are relieved, and repair is promoted. Experiments show that the traditional Chinese medicine composition is remarkable in curative effect and good in safety, and a novel efficient treatment strategy is provided for acute gouty arthritis.

The invention relates to the technical field of biological medicines, and particularly discloses an application of Dehydrovomigol sensitized bevacizumab in treatment of cervical cancer. The invention further relates to a preparation method of the Dehydrovomigol sensitized bevacizumab. Compared with a bevacizumab single drug, the effect of the bevacizumab on growth and proliferation inhibition, invasion blocking and angiogenesis inhibition of cervical cancer cells can be remarkably enhanced by combining the Dehydrovomifolol, and the drug resistance of the bevacizumab is reversed. In different experimental models, the Q value of the combination scheme is greater than or equal to 1.15, and the stable synergistic anti-cervical cancer effect is shown. Dehydrovomifolol realizes the effect of enhancing the anti-cervical cancer activity of the bevacizumab by virtue of triple mechanisms of reversing drug resistance, enhancing anti-angiogenesis and regulating an immune microenvironment. According to the combination scheme, the anti-cervical cancer curative effect can be improved, the clinical medication dosage of bevacizumab is reduced, the occurrence risk of toxic and side effects such as hypertension and proteinuria is reduced, and a novel, safe and efficient treatment strategy is provided for cervical cancer treatment.

This invention provides a genetically engineered biomimetic microsphere for hydration remodeling, its preparation method, and its application, belonging to the field of biomedical technology. This invention develops an injectable composite system, GBA / SRGN@HADA@GelMA, which possesses the ability to regulate hydration and intervene in genes through interface biomimetic design and multi-level functional integration. It uses HADA as a moisturizing outer layer, provides mechanical support through GelMA microspheres, and achieves targeted delivery of SRGN siRNA through G5-GBA loading, thereby achieving synergistic regulation of the degenerative nucleus pulposus microenvironment. GBA / SRGN@HADA@GelMA reduces the expression of inflammatory factors and matrix degradation genes, and significantly promotes the accumulation of HA and lubricating proteins. This enhances the water retention capacity and interfacial lubrication of the nucleus pulposus, thereby improving compressive elasticity and energy absorption capacity. This invention is the first to combine continuous water regulation, lubrication, mechanical buffering, and extracellular matrix homeostasis regulation to synergistically delay intervertebral disc degeneration, providing an excellent treatment strategy for degenerative intervertebral disc diseases.

The invention relates to the technical field of biological medicines, and particularly discloses application of ebbeselenium in preparation of a medicine for treating male delayed gonadal hypofunction. After the ebbeselenium is adopted for intervention, the autophagy activity of testicular interstitial cells of old mice is increased, lipid autophagy is enhanced, testosterone synthesis is promoted, the serum testosterone level is remarkably improved, and the symptoms of male delayed hypogonadism (LOH) are effectively relieved; ebbeselenium simultaneously shows a relatively good delaying effect on senescence of a plurality of organs. The ebbeselenium can improve the reproductive capacity, the behavior memory capacity, the athletic capacity and the metabolic function of old mice at the same time, and synergistic and effective treatment of low serum testosterone and LOH complications is achieved. Besides, by enhancing the molecular reduction effect of PRDX1 targeting ATG4B, the ebbeselenium regulates and controls the autophagy pathway of testicular interstitial cells and enhances the functions of the testicular interstitial cells so as to promote synthesis of testosterone, and a new treatment strategy is provided for treatment of LOH.

The invention belongs to the technical field of biological medicine, and particularly relates to a single-domain antibody VHH-L1 targeting LINGO-1 protein, and the amino acid sequence of the single-domain antibody VHH-L1 is shown as SEQ ID NO: 1. The single-domain antibody has nanomole-level high affinity and excellent specificity, can effectively block the interaction between LINGO-1 and ligands thereof, and remarkably promotes differentiation and myelination of oligodendroglia cells. The invention further provides a neural stem cell subjected to genetic engineering modification, and the neural stem cell can stably and continuously secrete the single-domain antibody VHH-L1. In a spinal cord injury animal model, the engineered stem cell shows an excellent treatment effect, can significantly promote motor function recovery, axon regeneration and myelin sheath repair, and effectively inhibits glial scar formation. The double advantages of cell therapy and long-acting protein delivery are fused, and a brand new efficient treatment strategy is provided for demyelination diseases such as multiple sclerosis and spinal cord injury.

The invention relates to the technical field of medicines, in particular to a composition with ingenane diterpenoid compounds as chemotherapeutic drug sensitizers and application of the composition. The chemotherapeutic drug sensitizer and the composition thereof provided by the invention can be used as the chemotherapeutic drug sensitizer, especially the sensitizer of breast cancer treatment drugs, and can be used for increasing the sensitivity of breast cancer cells to the chemotherapeutic drugs by inhibiting CHK1 (Ser345) phosphorylation so as to realize sensitization and provide a new treatment strategy for treating breast cancer.

The invention provides a cancer subtype classification method, system, equipment and program product based on ferroptosis related miRNA, and belongs to the field of intelligent medical treatment. The breast cancer is divided into four subtypes on the basis of ferroptosis related miRNA, the breast cancer FAP + subtype is identified on the basis of ferroptosis activity, the molecular characteristics of the FAP + subtype of an individual breast cancer patient are measured by establishing FAPscore, and the higher the FAPscore is, the more remarkable the FAP + subtype characteristics of the breast cancer patient are. The invention also finds that FAPscore can be used for predicting response, prognosis and drug sensitivity of individual cancer patients to immunotherapy response, and the discovery has wide cross-cancer species applicability and is not limited to breast cancer. The invention provides a new insight for a more effective and individualized treatment strategy of cancer.

The present application belongs to the field of biological medicine and molecular biology technology, and particularly relates to a marker for predicting the occurrence of repeated implantation failure and application thereof. The present application finds that abnormal lipid peroxidation in uterine epithelium can cause implantation defects, and the lipid peroxidation level of the uterus in patients with repeated implantation failure or repeated spontaneous abortion is enhanced, wherein the content of active aldehyde substance MDA and non-heme iron in serum can be used as a new non-invasive clinical index for predicting RIF patients; further, eliminating uterine lipid ROS to improve endometrial receptivity can be used as a potential new treatment strategy to improve embryo implantation and clinical pregnancy rate, and therefore has good practical application value.

This application relates to the field of biomedical technology and discloses the application of juniperol or its derivatives in the preparation of drugs that inhibit Drp1-mediated excessive mitochondrial division. This application verifies through in vitro and in vivo experiments that juniperol can inhibit phosphorylation at the Ser616 site of Drp1 and Drp1 mitochondrial translocation, thereby inhibiting Drp1-mediated excessive mitochondrial division. This demonstrates a good therapeutic effect on mitochondrial excessive division-related diseases such as inflammatory bowel disease, providing a new therapeutic strategy for the treatment of these diseases and possessing significant clinical implications.

The invention provides an application of hederagenin in preparation of a medicine used as an SKP2 degradation agent, and particularly provides an application of hederagenin in preparation of a medicine used as an SKP2 degradation agent. The invention also provides a PROTAC compound, which comprises a target protein POI ligand, an E3 ubiquitin ligase ligand and a linking chain Linker, the general formula of the ligand-Linker-E3 ligase ligand is as follows: a POI ligand-Linker-E3 ligase ligand. The invention also provides a preparation method and application of the PROTAC compound. The PROTAC design based on HED improves the tumor tissue targeting property, and shows low toxicity in an in-vivo experiment. The invention provides a novel SKP2 (SKP2) degradation agent. The degradation agent is expected to be capable of efficiently inducing ubiquitination degradation of SKP2 protein, and a treatment strategy with higher potential and clinical application prospect is provided for overcoming the limitation of the prior art by enhancing the specific killing capability on SKP2 high-expression tumor cells and verifying the remarkable tumor inhibition effect and good safety of the degradation agent in an animal model.

The application discloses application of a benzimidazolone compound in preparation of a medicine for treating intervertebral disc degeneration. 11 H 14 N4O2, and has a CAS number of 881591-33-9. The application provides an innovative treatment strategy capable of intervening in an early stage of the disease and influencing disease progression from a cause level by targeting activation of SOD1 activity which is a newly found pathogenic link of intervertebral disc degeneration.

The invention relates to the field of biotechnology and medicine, and discloses a polypeptide targeting molecular chaperonin TRIC / CCT and application thereof. The sequence of the polypeptide is consistent with or truncated from the C-terminal sequence of a CCT subunit, and the polypeptide can be competitively combined with CRL4-DCAF12 ubiquitin ligase, so that the ubiquitination of the CCT subunit is reduced, and the formation of a TRIC / CCT compound is inhibited; the polypeptide inhibits the formation of a TRIC / CCT compound and blocks the activation of key metastasis promoting signal channels such as YAP, STAT3 and mTOR, thereby inhibiting the metastasis of lung cancer. According to systematic in-vivo and in-vitro experiments, the compound has excellent performance in the aspect of inhibiting lung cancer cell migration and metastasis, has the characteristics of clear target spot, clear action mechanism and the like, and provides a new treatment strategy for developing a new generation of lung cancer metastasis resisting medicines.

The invention discloses a plant lactobacillus AR195 strain and application thereof in preparation of a medicine for preventing and / or treating lung cancer, and belongs to the technical field of microorganisms. Through verification, the plant lactobacillus AR195 can inhibit the growth of lung cancer cells, also has certain prevention and treatment effects in a lung cancer mouse model, and can reduce the tumor burden of a BALB / c mouse lung cancer model by reducing MMP9 secretion, so that the plant lactobacillus AR195 can be used for preventing and assisting in treating lung cancer. Meanwhile, the accumulation of the AR195 bacteria in the lung can be improved to the maximum extent through atomization administration, and meanwhile, the adverse side effects of the whole body are reduced. A new drug source is provided for treatment of lung cancer, a novel treatment strategy is provided for treatment of lung cancer by probiotics, and treatment of lung cancer and development of a novel treatment method are facilitated. Meanwhile, the application range of the plant lactobacillus AR195 strain is widened, and a novel treatment strategy is provided for a potential mechanism of treating lung cancer by probiotics.

The invention discloses a pharmaceutical composition for treating post-infection cough and a preparation method thereof. The traditional Chinese medicine composition provided by the invention dispels wind and freezes lung to relieve exterior syndrome, eliminates dampness and strengthens spleen to treat middle energizer and depresses qi and reduces phlegm to relieve cough, and the whole formula combines dredging and tonifying and orderly freeing and descending, and embodies the formula characteristics of simultaneous regulation of lung and spleen and simultaneous treatment of principal and subordinate symptoms. The medicines are matched to dispel lung channel wind to stop spasm, and also can dissipate dampness with aromatics, invigorate the spleen to eliminate phlegm sources, tonify qi to strengthen superficies to tonify deficiency, and achieve the effects of dispelling wind and ventilating lung, eliminating dampness and phlegm, depressing qi and relieving cough. The traditional Chinese medicine composition directly focuses on the pathogenesis of cough with wind evil with dampness and adverse rising of lung qi after infection, and can be used for treating the symptoms of cough with exuberant wind and dampness obstruction after infection, such as throat itching and cough, frequent and severe cough, sticky expectoration, chest distress, epigastric fullness, fatigue and the like. The invention provides a new treatment strategy for the post-infection cough, and has a wide clinical application prospect.

The invention belongs to the technical field of animal model construction, and particularly provides a construction method and application of a mouse non-alcoholic fatty liver model, and the construction method comprises the following steps: S1, selecting an experimental mouse; s2, a high nitrogen compound aqueous solution with the mass concentration of 4-10 mg / mL is prepared; s3, according to the dosage, the dosage and the administration time, the prepared high-nitrogen compound aqueous solution is fed through the intragastric administration, and the non-alcoholic fatty liver animal model is obtained, the problems that an existing non-alcoholic fatty liver animal model is long in modeling time and expensive in modeling are solved, and the non-alcoholic fatty liver animal model does not need to be fed with high-fat feed, and is simple, convenient and feasible, low in cost, good in repeatability and stable; the establishment period of the non-alcoholic fatty liver animal model can be effectively shortened, the time cost of the medical research of the NAFLD is greatly saved, and a good animal model is provided for researching the pathogenesis and treatment strategy of the NAFLD.

The invention relates to application of ITGBL1 as a medicine for treating obesity and osteoporosis. The invention provides a treatment strategy based on a key molecular mechanism of obesity and osteoporosis associated pathogenesis. The invention discloses ITGBL1 treatment which can inhibit obesity and osteoporosis.

The invention belongs to the technical field of biological medicine, and relates to application of miRNA targeted regulation in treatment of acute respiratory distress syndrome, in particular to application of a miR-144 inhibitor in preparation of a medicine for improving glucocorticoid treatment sensitivity of an ARDS patient. Research on a lipopolysaccharide-induced ARDS rat model finds that miR-144 participates in regulation and control of glucocorticoid receptor beta (GR beta) and NF-kappa B signal pathways in the ARDS inflammatory reaction process, the number of neutrophils in alveolar lavage fluid and the level of inflammatory factors such as IL-6 and TNF-alpha can be remarkably reduced by using the miR-144 inhibitor and glucocorticoid for treatment, and the application of the miR-144 inhibitor to treatment of the pulmonary alveolar lavage fluid in the treatment of the pulmonary alveolar lavage fluid is broad. The wet-to-dry ratio and pathological injury score of lung tissues are reduced, and GR beta and NF-kappa B expression is inhibited, so that the anti-inflammatory effect of glucocorticoid is remarkably enhanced. The invention provides a treatment strategy for improving glucocorticoid resistance of ARDS patients by taking miR-144 as a target for the first time, and provides a new drug target and a technical scheme for accurate treatment of ARDS.

The invention relates to the technical field of biomedicine and pharmacy, and discloses application of polypeptide in preparation of a medicine for treating and / or preventing depression. An IL-33 / ST2 signal channel in an LS brain region is a key endogenous protection mechanism for maintaining normal emotion, and by constructing a CSDS depression mouse model for verification, the 81st-95th amino acid sequence of the IL-33 protein is determined to be a core active fragment of the IL-33 protein combined with an ST2 receptor and exerting an anti-depression function. Experiments prove that no matter through intraperitoneal injection or LS brain region local injection, the polypeptide can significantly improve mouse depression-like behaviors induced by a CSDS or LPS model. The polypeptide provided by the invention is small in molecular weight, can pass through a blood brain barrier after being fused with TAT, and provides important candidate molecules and treatment strategies for developing novel and effective antidepressant drugs.

The invention belongs to the technical field of biological medicines, and particularly relates to a pharmaceutical composition containing carboxamide triazole or pharmaceutically acceptable salts thereof and application of the pharmaceutical composition in preparation of medicines for preventing or treating fibrosis-related diseases. Specifically, the invention discovers that the carboxylamine triazole orotate (CTO) can directly inhibit fibroblast collagen generation and cross-linking maturation, so that the fibrosis degree is reduced; when the polypeptide is combined with a PD-1 antibody, collagen deposition in tumor tissues can be reduced by inducing normalization of a tumor matrix in a synergistic manner, the tumor permeation concentration of chemotherapeutic drugs is remarkably enhanced, and the anti-tumor curative effect is improved. The invention can be applied to the treatment of various matrix dense solid tumors including pancreatic cancer, breast cancer, colorectal cancer and lung adenocarcinoma, and is expanded for intervention of fibrosis-related diseases, thereby providing a new treatment strategy for improving the efficacy of chemotherapeutic drugs and improving immunotherapy response through targeted matrix remodeling.

The invention provides a synergistic treatment pharmaceutical composition for preventing and treating recurrence after hepatocellular carcinoma thermal ablation and application of the synergistic treatment pharmaceutical composition. Aiming at malignant tumor progression driven by ACSS3 gene silencing after thermal ablation, an epigenetic editing technology is innovatively combined with metabolite supplementation, and a preparation for specifically activating or promoting ACSS3 gene expression and sodium propionate are cooperatively used, so that ACSS3 can be remarkably reactivated or expression can be promoted in a xenograft model derived from a cell line and a patient; the compound can be used for recovering propionyl-coenzyme A synthesis and normal propionic acid metabolism and inhibiting fatty acid beta-oxidation, so that the growth and metastasis of post-ablation hepatocellular carcinoma (HCC) are effectively blocked, and the limitation of a single therapy is overcome. A clearer mechanism target is provided for preventing recurrence after HCC thermal ablation, meanwhile, the prepared targeting nano-liposome preparation has a synergistic effect, and as a brand-new treatment strategy, the defect that intervention on recurrence roots is insufficient in the prior art is overcome.

The invention belongs to the technical field of biological medicine and molecular biology, and provides a hypertrophic cardiomyopathy virulence gene MYH7c.794Cgt; the invention relates to T (p.Thr265Ile) and an application thereof. The MYH7 gene mutation is located on the ninth exon, the 794th base is mutated from C to T, namely ACC is mutated to ATC, and the 265th amino acid in the coded amino acid sequence is mutated from threonine to isoleucine. The mutation induces cardiac hypertrophy by disrupting energy metabolism-this defect occurs prior to the occurrence of systolic dysfunction. Along with increasingly prominent status of precision medicine in cardiovascular treatment, a treatment strategy aiming at an upstream pathological process (such as energy homeostasis and mitochondrial dysfunction) provides a way with a wide prospect for preventing and treating MYH7-related hypertrophic cardiomyopathy. MYH7 gene screening has important values in the aspects of promoting early diagnosis, guiding timely treatment intervention and realizing risk-based prevention and management.